section name header

Pronunciation

en-koe-RAF-e-nib

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Indications

High Alert

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed (86%) following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A4 and CYP2C19 isoenzymes. Primarily excreted as metabolites in feces (42%) and urine (45%).

Half-life: 3.5 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown2 hr24 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: cardiomyopathy, QT interval prolongation.

Derm: alopecia, dry skin, hyperkeratosis, pruritus, rash, BASAL CELL CARCINOMA, CUTANEOUS SQUAMOUS CELL CARCINOMA, nodule formation.

EENT: uveitis.

Endo: hyperglycemia.

F and E: hypermagnesemia, hyponatremia.

GI: liver enzymes, abdominal pain, constipation, nausea, vomiting, GI HEMORRHAGE, PANCREATITIS.

GU: serum creatinine, fertility (males).

Hemat: anemia, bleeding, leukopenia, lymphopenia, neutropenia.

MS: arthralgia, myalgia.

Neuro: dizziness, fatigue, headache, peripheral neuropathy, facial paralysis, INTRACRANIAL HEMORRHAGE.
Misc: fever, HYPERSENSITIVITY REACTIONS, MALIGNANCY.

Interactions

Drug-Drug:

Drug-Natural Products:

Drug-Food:

Route/Dosage

BRAF V600E or V600K Mutation-Positive Unresectable or Metastatic Melanoma and BRAF V600E Mutation-Positive Metastatic NSCLC

BRAF V600E Mutation-Positive Metastatic Colorectal Cancer

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Braftovi